Asthma

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

A new survey shows patients and family members prefer telemedicine physician visits as much as they do in-person appointments—or even more so than the latter.

A new assessment shows patients younger and older than 40 years both benefit in exacerbation rate and pre-bronchodilator FEV1.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

Asthma burden among women can vary based on their age. Are there varying methods of care?

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.

The drug class has become a mainstay in clinical practice and treatment plans. But could it reach greater, and wider, indications?

Investigators found similar rescue treatment use among patients who do and do not have frequent exacerbations.

A study observing the effect of formulary changes to children with asthma show FEV and FEF scores worsened significantly when switching inhaler types.

The indication makes it the first respiratory biologic available either at home or in a professional setting, with eight-week maintenance dosing.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.

On this episode of the DocTalk Podcast, Lakiea Wright, MD, of Brigham and Women's Hospital and Thermo Fisher Scientific, discusses the impact of changing seasons and climate on allergies and asthma.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

The biologic becomes the first in its drug class to be indicated for patients aged 6-11 years old with the difficult-to-treat condition.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.